Access to the life science market can be a headache for multinational pharma and medical device companies, let alone small-medium sized enterprises (SMEs). SMEs can face significant challenges to introduce new and innovative products into the health and social care market.
The Innovation Nexus provides a single point of access for SMEs in the life science sector to a network of specialist support within Greater Manchester.
The Innovation Nexus is a gateway to a holistic business growth support offering, focused on the specialist needs of life science SMEs, delivered through a coherent support strategy and an all-inclusive approach to helping businesses develop their growth strategies.
The aim of the Innovation Nexus is to deliver long-term health and wealth benefits to Greater Manchester through investment, innovation, education and business growth, ultimately improving the health and wellbeing of the Greater Manchester population (and beyond).
INDUSTRY PARTNERSHIP WILL BE A KEY COMPONENT OF HOW HEALTH SYSTEMS WILL IMPROVE HEALTH OUTCOMES FOR THE POPULATIONS THEY SERVE
The challenge for healthcare businesses
Companies, especially SMEs, can face significant challenges to introduce their new and innovative products into the NHS. The complexity of public procurement, patient safety and a risk averse culture across multiple organisations can be daunting. The Innovation Nexus aims to provide a single source of resource that can help companies, particularly SMEs, understand the steps that need to be taken to support their business planning and engage with the NHS more easily, thus progressing the adoption of their innovation at pace and with fewer unanticipated obstacles.
How can the Innovation Nexus help?
Help with navigating NHS procurement
Information about funding and investment
Help with setting up a trial of your innovation
Information on science parks and office locations in the GM AHSN footprint
Connections to organisations that can help you progress your innovation
Speak directly to a GM AHSN advisor with NHS expertise
Early Diagnosis Industry Challenge - 22 February to 30 March 2017
The national Cancer Vanguard recently launched a unique and innovative opportunity for a select group of industry, academic or third sector partners to work on a project improving the early diagnosis of cancer.
Dr Linda Magee, GM AHSN’s Executive Director for Industry & Wealth, and Richard Deed, Technology Director at TRUSTECH will be assessing applications for the call, which launched 22 February and closes at 16.00 on March 30.
The aim of this challenge is to engage expertise from outside the NHS to undertake a small number of high impact projects (five to eight) which will ultimately lead to a tangible improvement in the earlier diagnosis of cancer in the NHS. There is a specific focus on two outcomes:
- Increasing the proportion of cancers detected at stage 1 & 2 (stage shifts)
- Reducing the proportion of cancers detected through presentation at A&E
The Industry Challenge team is looking for a wide range of early diagnosis projects, which would benefit from access to the national Cancer Vanguard’s knowledge and resources. Projects should launch from May 2017 and conclude by end April 2018.
The Cancer Vanguard will be holding an information event from 15:00-17:00 on 16 March, at 52 Club, Bonham Carter House, 52 Gower St, London WC1E 6EB. If you would like to attend, please register by emailing CancerVanguard@uclh.nhs.uk
The application forms and FAQs document are available to download below. If you have any questions about the call which are not answered in the FAQs, please contact CancerVanguard@uclh.nhs.uk
Information and guidance
Access information and guidance on a range of topics related to working with and selling to the NHS, and find clear signposts to organisations that can help you achieve your goals.